AGÕæÈ˹ٷ½

STOCK TITAN

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has granted stock options for 127,000 common shares to three new employees as employment inducement awards. The grants were approved by the Company's Compensation Committee under the Inducement Plan.

The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly thereafter, contingent on continued employment. These grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.

ADC Therapeutics (NYSE: ADCT), azienda leader nel settore degli anticorpi coniugati a uso commerciale, ha concesso opzioni su 127.000 azioni ordinarie a tre nuovi dipendenti come incentivi all'assunzione. Le assegnazioni sono state approvate dal Comitato per la Remunerazione della Società secondo il Piano di Incentivazione.

Le opzioni matureranno in un periodo di quattro anni, con il 25% che matura al primo anniversario e il resto che matura mensilmente successivamente, a condizione che l'impiego continui. Queste assegnazioni sono state effettuate in conformità con l'esenzione per incentivi all'assunzione prevista dalla Regola 303A.08 del Manuale per le Società Quotata alla NYSE.

ADC Therapeutics (NYSE: ADCT), líder en el mercado comercial de conjugados de anticuerpos y fármacos, ha otorgado opciones sobre acciones para 127,000 acciones comunes a tres nuevos empleados como premios por inducción laboral. Las concesiones fueron aprobadas por el Comité de Compensación de la Compañía bajo el Plan de Inducción.

Las opciones se consolidarán durante un período de cuatro años, con un 25% consolidado en el primer aniversario y el resto consolidándose mensualmente después, condicionado a la continuidad del empleo. Estas concesiones se hicieron bajo la exención por inducción laboral de la Regla 303A.08 del Manual de Empresas Listadas de la NYSE.

ADC Therapeutics (NYSE: ADCT)ëŠ� ìƒì—… 단계ì� í•­ì²´ 약물 ì ‘í•©ì²� 분야 ì„ ë„ ê¸°ì—…ìœ¼ë¡œ, ì‹ ê·œ ì§ì› 3명ì—ê²� 127,000 보통ì£� 스톡옵션ì� ê³ ìš© ìœ ì¸ ë³´ìƒìœ¼ë¡œ 부여했습니ë‹�. ì� 부여는 회사 ë³´ìƒ ìœ„ì›íšŒê°€ ìœ ì¸ ê³„íšì—� ë”°ë¼ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤.

옵션ì¶Ä 4ë…� 기간ì—� ê±¸ì³ ë² ìŠ¤íŒ…ë˜ë©�, ì²� 기ë…ì¼ì— 25%ê°€ 베스팅ë˜ê³� 나머지ëŠ� 매월 베스팅ë˜ë©� ê³„ì† ê³ ìš© ìƒíƒœë¥� 조건으로 합니ë‹�. ì� 부여는 NYSE ìƒìž¥íšŒì‚¬ 매뉴ì–� 규칙 303A.08ì� ê³ ìš© ìœ ì¸ ë©´ì œì—� ë”°ë¼ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�.

ADC Therapeutics (NYSE : ADCT), un leader en phase commerciale dans les conjugués anticorps-médicaments, a accordé des options d'achat d'actions pour 127 000 actions ordinaires à trois nouveaux employés en tant que récompenses d'incitation à l'embauche. Les attributions ont été approuvées par le comité de rémunération de la société dans le cadre du plan d'incitation.

Les options seront acquises sur une période de quatre ans, avec 25 % acquis à la première année et le reste acquis mensuellement par la suite, sous réserve de la poursuite de l'emploi. Ces attributions ont été faites conformément à l'exemption d'incitation à l'embauche de la règle 303A.08 du manuel des sociétés cotées de la NYSE.

ADC Therapeutics (NYSE: ADCT), ein führendes Unternehmen im Bereich Antikörper-Wirkstoff-Konjugate in der kommerziellen Phase, hat Aktienoptionen für 127.000 Stammaktien an drei neue Mitarbeiter als Einstellungsanreize gewährt. Die Zuteilungen wurden vom Vergütungsausschuss des Unternehmens gemäß dem Anreizplan genehmigt.

Die Optionen werden über einen Zeitraum von vier Jahren unverfallbar, wobei 25 % am ersten Jahrestag unverfallbar werden und der Rest danach monatlich, vorbehaltlich einer fortdauernden Beschäftigung. Diese Zuteilungen erfolgten unter der Beschäftigungsanreiz-Ausnahme gemäß Regel 303A.08 des NYSE Listed Company Manuals.

Positive
  • None.
Negative
  • None.

LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025 (each, a "Grant").

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.

Headquartered in Lausanne (µþ¾±´Ç±èô±ô±ð), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at  and follow us on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors and Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040

Cision View original content to download multimedia:

SOURCE ADC Therapeutics SA

FAQ

What stock options did ADC Therapeutics (ADCT) grant to new employees in August 2025?

ADC Therapeutics granted options to purchase 127,000 common shares to three new employees as employment inducement awards on August 1, 2025.

What is the vesting schedule for ADCT's employee stock options granted in August 2025?

The options vest 25% on the first anniversary of the grant date, followed by 1/48th monthly thereafter, fully vesting after four years, subject to continued employment.

Why did ADC Therapeutics issue these stock options under NYSE Rule 303A.08?

The options were granted as material inducement awards to new employees under NYSE Rule 303A.08, which provides an employment inducement exemption for equity grants.

How many new employees received stock options from ADC Therapeutics in August 2025?

Three new employees received stock option grants from ADC Therapeutics on August 1, 2025.
Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Latest SEC Filings

ADCT Stock Data

330.05M
71.77M
20.64%
63.17%
5.48%
Biotechnology
Pharmaceutical Preparations
Switzerland
EPALINGES